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This study was planned to investigate the prevalence and clinical features of the illnesses associated with
human bocavirus (hBoV) in children with acute disease. We prospectively enrolled all subjects aged less than
15 years attending an emergency room in Milan, Italy, on Wednesdays and Sundays between 1 November 2004
and 31 March 2005 for any acute medical reason, excluding surgical diseases and trauma. Nasopharyngeal
swabs were collected at admission to detect hBoV; influenza A and B viruses; respiratory syncytial virus;
human metapneumovirus; parainfluenza viruses 1, 2, 3, and 4; rhinovirus; adenovirus; and coronaviruses
229E, OC43, NL63, and HKU1 by real-time PCR. Among the 1,332 enrolled children, hBoV was the fifth most
frequently detected virus (7.4%). The rate of hBoV coinfections with other viruses was significantly higher than
for the other viruses (50.5% versus 27.5%; P < 0.0001). Eighty-nine of the 99 hBoV-positive children (89.9%)
had a respiratory tract infection, and 10 (10.1%) had gastroenteritis. hBoV coinfections had a significantly
greater clinical and socioeconomic impact on the infected children and their households than hBoV infection
alone. In conclusion, these findings show that the role of hBoV infection alone seems marginal in children
attending an emergency room for acute disease; its clinical and socioeconomic importance becomes relevant
only when it is associated with other viruses.
Two years ago, a previously unknown human parvovirus
called human bocavirus (hBoV) was identified in Swedish chil-
dren suffering from respiratory tract infection (RTI) (2), and
subsequent studies carried out in different geographic areas
have shown that it circulates widely and can be found in a
significant percentage of subjects with upper or lower respira-
tory tract disease, mainly young children (1, 4–7, 10, 11, 16, 17,
19–22, 24, 25, 28, 30, 32, 33, 39). Healthy carriers of this virus
have not been identified. Thus, this strongly supports the hy-
pothesis that hBoV may really be the cause of the diagnosed
disease when it is detected in respiratory secretions (3, 26).
Epidemiological studies seem to indicate that, in young chil-
dren, hBoV is less important than respiratory syncytial virus
(RSV) but at least as important as influenza viruses, human
metapneumovirus (hMPV), adenovirus, and parainfluenza vi-
rus type 3 (1, 4, 11, 16, 19, 25). However, the full spectrum of
the diseases associated with hBoV, the prevalence of compli-
cations, the frequency of the spread of hBoV in households
and close contacts, and hBoV’s social consequences are not
known. Moreover, the role of coinfections with hBoV and
other respiratory viruses remains to be clarified. This informa-
tion is essential for establishing the real impact of hBoV in-
fections in pediatrics and deciding whether specific preventive
or therapeutic measures need to be developed.
The aim of this study was to investigate the prevalence and
clinical features of the illnesses associated with hBoV infec-
tions in children attending an emergency room.
MATERIALS AND METHODS
Study design. We prospectively enrolled all subjects aged less than 15 years
attending the emergency room of the Institute of Pediatrics, University of Milan,
Milan, Italy, on Wednesdays and Sundays between 1 November 2004 and 31
March 2005 for any acute medical reason, excluding surgical diseases and
trauma. The study protocol was approved by the Institutional Review Board of
the University of Milan, Milan, Italy. The written informed consent of a parent
or legal guardian was required, and older children were asked for their assent.
Patient enrollment and evaluation. Upon enrollment, systematic records were
made of the patients’ demographic characteristics and medical history using
standardized written questionnaires (8, 12, 13). The questions included detailed
disease signs and symptoms, laboratory tests and/or radiological examinations,
prescribed drug therapy, chronic underlying diseases, family size and the number
of siblings, parents’ education and occupations, family living conditions, and
information about child care attendance. After a complete physical examination,
the children were divided into different disease groups on the basis of signs and
symptoms, using well-established criteria (14). Fever was defined as the presence
of an axillary temperature of 37.8°C or a rectal temperature of 38°C (14).
Upon enrollment, Virocult (Medical Wire and Equipment, Corsham, United
Kingdom) nasopharyngeal swabs were used to collect specimens for the detec-
tion of hBoV; influenza A and B viruses; RSV; hMPV; parainfluenza viruses 1,
2, 3, and 4; rhinovirus; adenovirus; and human coronaviruses (hCoVs) 229E,
OC43, NL63, and HKU1 by real-time PCR. Only one sample was taken from
each child, from which two aliquots were immediately obtained before they were
frozen at 80°C for analysis at the Department of Virology, Erasmus Medical
Center, Rotterdam, The Netherlands. Total nucleic acids were routinely isolated
on a MagnaPureLC isolation station (Roche Applied Science, Penzberg, Ger-
many). A universal internal control virus was used to monitor the process from
the isolation of nucleic acids until real-time detection (9, 12). The in-house
real-time PCR for hBoV and the internal control, phocine distemper virus, was
designed using primer express software (Applied Biosystems, Nieuwerkerk a/d
IJssel, The Netherlands). hBoV was detected in extracted DNA by PCR ampli-
fication of a 291-bp fragment of the NS1 gene, as previously described (1, 27).
Briefly, nucleic acids were extracted from 400 l of the nasopharyngeal aspirates,
and the DNA was eluted in 100 l of RNase-free water. The 20-l amplification
reaction mixture contained 5 l sample DNA, 10 l TaqMan universal PCR
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master mix (PE Applied Biosystems), 0.1 l bovine serum albumin (20 mg/ml),
300 nmol/liter of each primer (Boca-forward, GGA AGA GAC ACT GGC AGA
CAA; Boca-reverse, GGG TGT TCC TGA TGA TAT GAG C), and 150 nmol/
liter of the Boca probe (FAM-CTG CGG CTC CTG CTC CTG TGA T-
TAMRA, where FAM is 6-carboxyfluorescein and TAMRA is 6-carboxytetra-
methylrhodamine). Amplification was performed using an ABI 7500 instrument
under standard amplification conditions with the following settings: 95°C for 10
min and 42 cycles of 95°C for 15 s and 60°C for 1 min.
Real-time PCR for influenza A and B viruses; RSV; hMPV; parainfluenza
viruses 1, 2, 3, and 4; rhinovirus; adenovirus; and hCoVs 229E, OC43, NL63, and
HKU1 was performed as previously described (8, 9, 12, 13, 15, 18, 23, 34–38,
40, 41).
The medical histories of the children were reevaluated 5 to 7 days after
enrollment and until the resolution of their illness by means of interviews and
clinical examinations by trained investigators using standardized questionnaires
(8, 12, 13). During this evaluation, information was also obtained regarding acute
illnesses and related morbidity in their households. The children’s parents or
legal guardians were asked to answer questions regarding the outcome of their
child’s disease (e.g., final diagnosis, administered medication, hospitalization,
duration of signs/symptoms, medical visits, examinations, and number of lost
school days) and the involvement of other family members (e.g., diseases in
households, medication, hospitalization, medical visits, number of working days
lost by parents to care for themselves and their children, and the number of
domestic help days required to care for the ill children). All the data were
verified from medical records.
Statistical analysis. The data were analyzed using SAS Windows v.12 (SAS
Institute, Cary, NC); a P value of 0.05 was considered statistically significant.
Parametric data were compared by analysis of variance; abnormally distributed
or nonparametric data were analyzed using the Kruskal-Wallis test. The cate-
gorical data were analyzed by means of contingency analysis and the chi-square
or Fisher test.
RESULTS
Study population. We enrolled 1,332 children aged less than
15 years (718 [53.9%] were male; mean age  standard devi-
ation, 3.32  3.26 years); 779 (58.5%) had evidence of acute
RTI, 203 (15.2%) had gastrointestinal disease, 86 (6.4%) had
fever without source, 49 (3.7%) had exanthematic disease, 41
(3.1%) had seizures with or without fever, 39 (2.9%) had ne-
phritic or nephrotic syndrome, 36 (2.7%) had skin and soft
tissue infections, 33 (2.5%) had meningitis/encephalitis, 31
(2.3%) had sepsis, 27 (2.0%) had bone or joint infection, 5
(0.4%) had a coagulation disorder, and 3 (0.3%) had conjunc-
tivitis.
Of the study children, 101 (7.6%) had evidence of chronic
underlying diseases: 60 (4.5%) had chronic asthma, 18 (1.3%)
had cystic fibrosis, 12 (0.9%) had hemodynamically significant
cardiac disease, 6 (0.5%) had chronic kidney insufficiency, and
5 (0.4%) had human immunodeficiency virus (HIV) infection.
Frequency of hBoV infection. hBoV was the fifth most fre-
quently detected virus and was identified in 99 children (7.4%).
The most frequently detected viruses were influenza viruses
(180 cases, 13.5%), whereas RSV was found in 161 patients
(12.1%), adenovirus in 123 (9.2%), rhinovirus in 101 (7.6%),
hCoVs in 53 (4.0%), parainfluenza viruses in 35 (2.6%), and
hMPV in 2 (0.2%).
Coinfections were demonstrated in 230/1,332 children
(17.3%). hBoV was the most frequent virus in coinfections,
being demonstrated together with at least one other respira-
tory virus in 50/99 hBoV-positive samples (50.5%; there were
13 subjects with adenovirus, 12 with influenza viruses, 8 with
RSV, 3 with CoVs, 3 with rhinovirus, 2 with parainfluenza
viruses, and 9 with multiple viruses). Coinfections in the pres-
ence of viruses different from hBoV were observed in 180/655
cases (27.5%). The rate of coinfections with hBoV and other
viruses was significantly higher than those for any combination
of other respiratory viruses (P  0.0001) (Table 1).
hBoV was detected in 89/779 children with RTIs (11.4%)
and 10/203 children with gastrointestinal disease (4.9%). No
other clinical diagnosis was associated with hBoV.
Table 2 shows the demographic characteristics of the chil-
TABLE 1. Frequency of hBoV infections
Virus detection
No. (%) of samples that were
hBoV
Positivea Negative
Infection with a single virus 49 (49.5)* 475 (72.5)
Coinfection with: 50 (50.5)* 180 (27.5)
One other virus 41 (41.4)** 180 (27.5)
Two other viruses 9 (9.1)** 0 (0.0)
Total 99 (100.0) 655 (100.0)
a P was 0.0001 (*) and P was 0.05 (**) versus children with hBoV-negative
samples. There was no other significant difference between the groups.




No. (%) of children of indicated age (yr)
Mean age (yr) (SD)
No. (%) of children
with chronic
underlying disease2 2–5 5
hBoV alone 49 29 (59.2) 36 (73.5)c, f 13 (26.5)b,d, f,g 0 (0.0)a,c,e, f,h 2.4 (2.5)a,b,e, f 0 (0.0)a
hBoV coinfection 50 29 (58.0) 28 (56.0)b, f 11 (22.0)b,d, f,g 11 (22.0)d,g 3.1 (2.6) 8 (16.0)
Influenza virus 151 76 (50.3) 46 (30.5) 66 (43.7) 39 (25.8)d,g 3.6 (2.9) 10 (6.7)
RSV 121 68 (56.2) 61 (50.4)b, f 51 (42.1) 9 (7.4)h 1.9 (1.8)a,c,e, f 9 (7.4)
Rhinovirus 74 39 (52.7) 39 (52.7)b, f 21 (28.4) 14 (18.9) 3.0 (2.9) 5 (6.8)
Adenovirus 70 41 (58.6) 39 (55.8)b, f 26 (37.1) 5 (7.1)h 2.3 (1.9)a,b,e, f 2 (2.9)
hCoVs 36 21 (58.3) 11 (30.6)b 15 (41.6) 10 (27.8) 3.6 (2.7) 3 (8.3)
Parainfluenza virus 21 12 (57.1) 12 (57.1) f 9 (42.9) 0 (0.0)h 1.7 (1.3)a,b,e, f 0 (0.0)
hMPV 2 1 (50.0) 0 (0.0) 0 (0.0) 2 (100.0) 6.6 (0.9) 0 (0.0)
a P  0.05 versus children with hBoV coinfection.
b P  0.05 versus children with influenza virus.
c P  0.0001 versus children with influenza virus.
d P  0.05 versus children with RSV.
e P  0.05 versus children with rhinovirus.
f P  0.05 versus children with hCoVs.
g P  0.05 versus children with parainfluenza virus.
h P  0.05 versus children with hMPV. No other significant between-group difference was observed.











dren with infections caused by a single virus or by hBoV asso-
ciated with other viruses. There was no significant between-
group difference in gender distribution. The age distribution
and mean age of the children with hBoV infection alone were
similar to those of the children with RSV, adenovirus, and
parainfluenza virus, but their mean age was less than that of
the children with hBoV coinfection, influenza, rhinovirus,
hCoV, or hMPV. Moreover, the presence of a chronic under-
lying disease was significantly less frequent in the children with
hBoV infection alone than in those with hBoV coinfection.
Among children with hBoV coinfection, five had chronic
asthma, two had hemodynamically significant cardiac disease,
and one had HIV infection; among children with influenza, six
had chronic asthma, two had cystic fibrosis, one had hemody-
namically significant cardiac disease, and one had chronic kid-
ney insufficiency; among children with RSV, three had chronic
asthma, two had cystic fibrosis, two had hemodynamically sig-
nificant cardiac disease, one had chronic kidney insufficiency,
and one had HIV infection; among children with rhinovirus
infection, two had chronic asthma, two had cystic fibrosis, and
one had hemodynamically significant cardiac disease; among
children with adenovirus infection, one had chronic kidney
insufficiency and one had HIV infection; among children with
hCoVs, two had chronic asthma and one had cystic fibrosis.
Clinical and socioeconomic relevance of hBoV infection in
infected children. Table 3 summarizes the clinical characteris-
tics of the children with infections caused by a single virus or by
hBoV associated with other viruses. Of the 99 hBoV-positive
children, 89 (89.9%) had RTIs and 10 (10.1%) gastroenteritis.
In the children with hBoV infection alone, upper RTIs (URTIs)
were the most frequently diagnosed diseases (85.7%), whereas
lower RTIs (LRTIs) were found in only 4.0%; the opposite was
true for children with hBoV coinfection. The prevalence of
URTIs in children with hBoV infection alone was higher than
that in the children with other viral infections, although influ-
enza virus, rhinovirus, adenovirus, hCoVs, and parainfluenza
virus were associated mainly with URTIs. On the other hand,
the prevalence of LRTIs was higher in the children with hBoV
coinfection or with RSV or hMPV than in the other groups.
Interestingly, among the other infections, the prevalence of
gastroenteritis was quite high regardless of the etiology of the
diseases, and there were similar prevalences of gastroenteritis
in children with hBoV infection alone or hBoV coinfection and
in children in the other viral groups.
Table 4 summarizes the clinical and socioeconomic impact
of the infections caused by a single virus or by hBoV associated
with other viruses on the children. The percentages of children
requiring laboratory tests and radiographic examinations upon
admission and the hospitalization rate were higher for the
children with hBoV coinfection than for those with hBoV
infection alone or those in the other viral groups, and the
median number of lost school days due to the admission illness
was also higher for the children with hBoV coinfection. Anti-
biotics were more frequently prescribed for the children with
hBoV infection alone or hBoV coinfection than for children in
the other viral groups, whereas the prescription of acetamin-
ophen was significantly more common for the children with
influenza. Steroids and aerosol therapy were prescribed more
frequently for the children with hBoV coinfection than for
those with hBoV infection alone or for those in the majority of
the other viral groups.
TABLE 3. Clinical characteristics of children with infections caused by a single virus or by hBoV associated with other viruses
Diagnosis






















URTI 42 (85.7)a,b,d,e, f, i 21 (42.0)b,d,e,g, i 100 (66.2) 39 (32.2) 46 (62.2) 43 (61.4) 25 (69.4) 16 (76.2) 0 (0.0)
Pharyngitis 27 (55.1)c 9 (42.8) 79 (52.3)c 27 (22.3) 30 (40.5)c 31 (44.3)c 24 (66.7)d 7 (33.3) 0 (0.0)
AOMj 9 (18.4)f 7 (14.0)f 14 (9.3) 9 (7.4) 10 (13.5) 9 (12.8) 0 (0.0) 5 (23.8) 0 (0.0)
Rhinosinusitis 6 (12.2)c 5 (10.0)c 7 (4.6) 3 (2.5) 6 (8.2) 3 (4.3) 1 (2.7) 4 (19.1) 0 (0.0)
LRTI 2 (4.0)a,b,d,e,i 24 (48.0)b,e, f,g,h 35 (23.2)c 69 (57.0)e, f,g,h 12 (16.2) 4 (5.8) 5 (13.9) 0 (0.0) 2 (100.0)
Acute bronchitis 1 (2.0)a,b,c 9 (18.0)f 18 (11.9) 14 (11.6) 6 (5.4) 2 (2.9) 2 (5.6) 0 (0.0) 1 (50.0)
Wheezing 1 (2.0)d 7 (14.0)c 6 (4.0)d 39 (32.2) 4 (5.4)d 0 (0.0) 1 (2.7)d 0 (0.0)c 1 (50.0)
Pneumonia 0 (0.0)a,c 8 (16.0)e, f 11 (7.3) 16 (13.2)e, f 2 (2.7) 2 (2.9) 2 (5.6) 0 (0.0) 0 (0.0)
Gastroenteritis 5 (10.2) 5 (10.0) 6 (4.0)f 11 (9.1) 8 (10.8) 18 (25.7) 4 (11.1) 3 (14.3) 0 (0.0)
Fever without
source
0 (0.0) 0 (0.0) 10 (6.6) 2 (1.7) 2 (2.7) 1 (1.4) 2 (5.6) 2 (9.5) 0 (0.0)
Exanthema 0 (0.0) 0 (0) 0 (0.0) 0 (0.0) 6 (8.1) 4 (5.7) 0 (0.0) 0 (0.0) 0 (0.0)
a P  0.05 versus children with hBoV coinfection.
b P  0.05 versus children with influenza virus.
c P  0.05 versus children with RSV.
d P  0.0001 versus children with RSV.
e P  0.05 versus children with rhinovirus.
f P  0.05 versus children with adenovirus.
g P  0.05 versus children with hCoVs.
h P  0.05 versus children with parainfluenza virus.
i P  0.05 versus children with hMPV. There was no other significant between-group difference.
j AOM, acute otitis media.











Clinical and socioeconomic impact of hBoV infection on
households. Table 5 summarizes the clinical and socioeco-
nomic impact on households of children with infections caused
by a single virus or by hBoV associated with other viruses. The
prevalence of infections similar to that of the study child, the
number of medical visits required, the median number of lost
working days because of household illnesses, and the median
number of lost school days because of sibling illnesses, as well
as the number of antibiotic and antipyretic prescriptions, were
all higher in the households of children with hBoV coinfection
and influenza than in those with hBoV infection alone or those
in the other viral groups. There was no significant between-
group difference in the household hospitalization rates.
DISCUSSION
Our findings show that the role of hBoV infection alone
seems to be marginal in children attending an emergency room
for acute disease and that it becomes important only when it is
associated with other viral pathogens. This conclusion is sup-
ported by the epidemiological and clinical data and confirmed
by the socioeconomic impact of hBoV infections.
Several recent studies have demonstrated that hBoV is fre-
quently isolated in children and that its presence is almost
always associated with URTI and/or LRTI (1, 4–7, 10, 11, 16,
17, 19–22, 24, 25, 28, 30–33, 39). Our data confirm this, as
hBoV was detected in 7.4% of the pediatric patients admitted
to our emergency room and in 11.4% of those with respiratory
problems. The frequency of hBoV infections in our study is in
the range of the data reported by other authors, who have
detected the virus in 1.5 to 19% of subjects with acute respi-
ratory illness (1, 4–7, 10, 11, 16, 17, 19–22, 24, 25, 28, 30–33,
39), a range that can at least partially be explained by the
different methods used to study the epidemiology of hBoV
infection. Our study was prospective, and the samples were
taken from all of the children admitted to the emergency room
for acute diseases, most of whom were sent home because they
TABLE 4. Clinical and socioeconomic impact on children with infections caused by a single virus or by hBoV associated with other viruses
Infection (no. of children)








examination Hospitalization Antibiotics Acetaminophen Steroids
Aerosol
therapy
hBoV alone (49) 13 (26.5)a 2 (4.1)a,c 2 (4.1)a 4 (1–16)a 30 (61.2)c,d,e, f 0 (0.0)b 1 (2.0)a,c 3 (6.1)a,c
hBoV coinfection (50) 25 (50.0) 11 (22.0) 10 (20.0) 14 (2–18) 39 (78.0)c,d,e, f,g 2 (4.0)b 9 (18.0) 15 (30.0)
Influenza virus (151) 35 (23.2)a 12 (8.0)a,c 7 (4.6)a,c,e 9.5 (7–10) 89 (58.9) 121 (80.1) 10 (6.7)a,c 9 (6.0)a,c
RSV (121) 24 (19.8)a 23 (19.0) 19 (15.7) 7 (5–14) 52 (43.0) 56 (46.3)b 19 (15.7) 34 (28.1)
Rhinovirus (74) 12 (16.2)a 4 (5.4)a,c 4 (5.4)a 0 (0–2)a 24 (32.4) 30 (40.5)b 8 (10.8) 5 (6.8)a,c
Adenovirus (70) 21 (30.0)a 1 (1.4)a,c 1 (1.4)a 2 (1–6)a 26 (37.1) 43 (61.4)b 4 (5.7)a,c 2 (2.9)a,c
hCoVs (36) 8 (22.2)a 1 (2.8)a,c 3 (8.3) 5 (2–7) 11 (30.6) 43 (61.4)b 0 (0.0)a,c 3 (8.3)
Parainfluenza virus (21) 3 (14.3)a 1 (4.8) 1 (4.8) 0 (0–1)a 7 (33.3) 11 (52.4)b 0 (0.0)a,c 1 (4.8)a,c
hMPV (2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0) 30 (61.2)c,d,e,f 0 (0.0)b 1 (2.0)a,c 3 (6.1)a,c
a P  0.05 versus children with hBoV coinfection.
b P  0.05 versus children with influenza virus.
c P  0.05 versus children with RSV.
d P  0.05 versus children with rhinovirus.
e P  0.05 versus children with adenovirus.
f P  0.05 versus children with hCoVs.
g P  0.05 versus children with parainfluenza virus. There was no other significant between-group difference.
TABLE 5. Clinical and socioeconomic impact on households of children with infections caused by a single virus
or by hBoV associated with other viruses
Infection (no. of children)
No. (%) Median no. (range) whomissed: No. (%) requiring:
With an infection
similar to that of
study child
Requiring a





hBoV alone (120) 14 (11.7)c 9 (7.5)b 1 (0–4)a,b 1 (0–2)a,b 0 (0.0) 4 (3.3)a 9 (7.5)b
hBoV coinfection (126) 21 (16.7)c,e 18 (14.3)c 5 (2–7) 3 (1–6) 1 (2.0) 14 (11.1) 20 (15.9)
Influenza virus (400) 71 (17.8)d,e 69 (17.2)d 5 (2–7) 4 (0–8) 4 (1.0) 36 (9.0) 69 (17.2)
RSV (310) 39 (12.6)c 30 (9.7)b 2 (1–5) 2 (1–6) 2 (0.6) 18 (5.8) 33 (10.6)
Rhinovirus (190) 9 (4.7) 5 (2.6) 2 (1–5) 2 (1–5) 0 (0.0) 4 (2.1)a,b 9 (4.7)a,b
Adenovirus (170) 14 (8.2) 12 (7.1)b 2 (1–5) 2 (1–6) 0 (0.0) 9 (5.3) 12 (7.1)b
HCoVs (90) 9 (10.0) 6 (6.7)b 1 (1–3)a,b 1 (0–2)a,b 0 (0.0) 3 (3.3) 6 (6.7)b
Parainfluenza virus (55) 4 (7.3) 3 (5.5)b 2 (1–3) 0 (0)a,b 0 (0.0) 2 (3.6) 3 (5.5)b
HMPV (6) 0 (0.0) 0 (0.0) 0 (0) 0 (0) 0 (0.0) 0 (0.0) 0 (0.0)
a P  0.05 versus children with hBoV coinfection.
b P  0.05 versus children with influenza virus.
c P  0.05 versus children with rhinovirus.
d P  0.0001 versus children with rhinovirus.
e P  0.05 versus children with adenovirus. There was no other significant difference between the different etiologic groups.











were affected by mild infection and some had no infection at
all. Most of the other studies included only hospitalized chil-
dren or children with LRTIs (1, 4–7, 10, 11, 16, 17, 19, 20, 22,
24, 25, 28, 30–33, 39). As hBoV infection alone seemed to
cause mainly mild diseases in our population, it is reasonable
to think that the incidence of hBoV infections is lower when
only severe diseases are considered.
About half of the respiratory samples in which hBoV was
identified came from children who were also infected by at
least one of the other respiratory viruses tested. A high inci-
dence of hBoV coinfections in children with respiratory dis-
eases has been reported in previous studies (1, 4, 11, 17, 25,
39), but their clinical significance is not clear. We found that
the frequency of hBoV coinfections was greater than that of
coinfections involving the other viruses. Furthermore, hBoV
infection alone was usually mild and the hBoV coinfections
were significantly more severe. The relatively benign nature of
hBoV is highlighted by the fact that the mean age of the
children with hBoV infection alone was significantly lower than
that of the children with hBoV coinfection and similar to that
of children with RSV; however, both hBoV coinfection and
RSV were more severe in clinical and socioeconomic terms.
Our data provide further information concerning the total
burden of hBoV infection. They not only demonstrate that
hBoV coinfections can be observed in children with chronic
underlying diseases, which underlines the importance of fur-
ther studies of the role of hBoV in chronically ill pediatric
patients, but also describe the clinical characteristics of hBoV
infection in more detail by revealing significant differences in
the presentations of hBoV infection alone and hBoV coinfec-
tion, as well as between hBoV infection alone and infections
due to other viruses. Furthermore, the fact that signs and
symptoms of acute gastroenteritis were the reason for attend-
ing the emergency room for about 10% of the children in
whom hBoV was detected offers a clinical explanation for the
recent demonstration of hBoV DNA in stool samples (29).
Finally, our data indicate that hBoV infection alone has a
marginal clinical and socioeconomic impact on infected chil-
dren, whereas hBoV coinfection seems to be associated with
higher direct and indirect costs, as it involves significantly more
examinations, hospitalization, lost school days, and different
drug therapies. In addition, and in line with the clinical data, an
hBoV coinfection increases direct and indirect family costs.
In conclusion, our data indicate that hBoV is a common
respiratory virus and suggest that, alone, it is associated mainly
with mild respiratory or gastrointestinal illnesses, but its clin-
ical and socioeconomic impact on infected children and their
families becomes significant when it is present in coinfections
with other viruses. Although further data are needed to con-
firm these findings, the systematic surveillance of hBoV infec-
tion in children with acute disease does not seem to be a
priority.
ACKNOWLEDGMENT
This study was supported in part by a grant from the Italian Ministry
of Universities (project no. 2005068289_001).
REFERENCES
1. Allander, T., T. Jartti, S. Gupta, H. G. Niesters, P. Lehtinen, R. Osterback,
T. Vuorinen, M. Waris, A. Bjerkner, A. Tiveljung-Lindell, B. G. van den
Hoogen, T. Hyypia, and O. Ruuskanen. 2007. Human bocavirus and acute
wheezing in children. Clin. Infect. Dis. 44:904–910.
2. Allander, T., M. T. Tammi, M. Eriksson, A. Bjerkner, A. Tiveljung-Lindell,
and B. Andersson. 2005. Cloning of a human parvovirus by molecular screen-
ing of respiratory tract samples. Proc. Natl. Acad. Sci. USA 102:12891–
12896.
3. Anderson, L. J. 2007. Human bocavirus: a new viral pathogen. Clin. Infect.
Dis. 44:911–912.
4. Arden, K. E., P. McErlean, M. D. Nissen, T. P. Sloots, and I. M. Mackay.
2006. Frequent detection of human rhinoviruses, paramyxoviruses, corona-
viruses, and bocavirus during acute respiratory tract infections. J. Med. Virol.
78:1232–1240.
5. Arnold, J. C., K. K. Singh, S. A. Spector, and M. H. Sawyer. 2006. Human
bocavirus: prevalence and clinical spectrum at a children’s hospital. Clin.
Infect. Dis. 43:283–288.
6. Bastien, N., K. Brandt, K. Dust, D. Ward, and Y. Li. 2006. Human bocavirus
infection, Canada. Emerg. Infect. Dis. 12:848–850.
7. Bastien, N., N. Chui, J. L. Robinson, B. E. Lee, K. Dust, L. Hart, and Y. Li.
2007. Detection of human bocavirus in Canadian children in a 1-year study.
J. Clin. Microbiol. 45:610–613.
8. Bosis, S., S. Esposito, H. G. M. Niesters, P. Crovari, A. D. M. E. Osterhaus,
and N. Principi. 2005. Impact of human metapneumovirus in childhood:
comparison with respiratory syncytial virus and influenza viruses. J. Med.
Virol. 75:101–104.
9. Bosis, S., S. Esposito, H. G. M. Niesters, E. Tremolati, S. Pas, N. Principi,
and A. D. M. Osterhaus. 2007. Coronavirus HKU1 in an Italian pre-term
infant with bronchiolitis. J. Clin. Virol. 38:251–253.
10. Catalano-Pons, C., M. Bue, H. Laude, F. Cattan, F. Moulin, C. Menanger, C.
Cosnes-Lambe, M. Chalumeau, C. Giraud, J. F. Meritet, F. Rozenberg, P.
Lebon, and D. Gendrel. 2007. Human bocavirus infection in hospitalized
children during winter. Pediatr. Infect. Dis. J. 26:959–960.
11. Choi, E. H., H. J. Lee, S. J. Kim, B. W. Eun, N. H. Kim, J. A. Lee, E. K. Song,
S. H. Kim, J. Y. Park, and J. Y. Sung. 2006. The association of newly
identified respiratory viruses with lower respiratory tract infections in Ko-
rean children, 2000–2005. Clin. Infect. Dis. 43:585–592.
12. Esposito, S., S. Bosis, H. G. M. Niesters, E. Tremolati, E. Begliatti, A.
Rognoni, C. Tagliabue, N. Principi, and A. D. M. Osterhaus. 2006. Impact of
human coronavirus infections in otherwise healthy children who attended an
emergency department. J. Med. Virol. 78:1609–1615.
13. Esposito, S., R. Gasparini, S. Bosis, P. Marchisio, C. Tagliabue, S. Tosi, C.
Bianchi, P. Crovari, and N. Principi. 2005. Clinical and socioeconomic
impact of influenza and respiratory syncytial virus (RSV) infection on
healthy children and their households. Clin. Microbiol. Infect. 11:933–936.
14. Feigin, R. D., and J. D. Cherry (ed.). 1998. Textbook of pediatric infectious
diseases, 4th ed. W. B. Saunders Company, Philadelphia, PA.
15. Fouchier, R. A., N. G. Hartwig, T. M. Bestebroer, B. Niemeyer, J. C. de Jong,
J. H. Simon, and A. D. Osterhaus. 2004. A previously undescribed corona-
virus associated with respiratory disease in humans. Proc. Natl. Acad. Sci.
USA 101:6212–6216.
16. Foulongne, V., Y. Olejnik, V. Perez, S. Elaerts, M. Rodie`re, and M. Segondy.
2006. Human bocavirus in French children. Emerg. Infect. Dis. 12:1251–
1253.
17. Fry, A. M., X. Lu, M. Chittaganpitch, T. Peret, J. Fischer, S. F. Dowell, L. J.
Anderson, D. Erdman, and S. J. Olsen. 2007. Human bocavirus: a novel
parvovirus epidemiologically associated with pneumonia requiring hospital-
ization in Thailand. J. Infect. Dis. 195:1038–1045.
18. Heim, A., C. Ebnet, G. Harste, and P. Pring-Akerblom. 2003. Rapid and
quantitative detection of human adenovirus DNA by real-time PCR. J. Med.
Virol. 70:228–239. (Erratum, 71:320.)
19. Kesebir, D., M. Vazquez, C. Weibel, E. D. Shapiro, D. Ferguson, M. L.
Landry, and J. S. Kahn. 2006. Human bocavirus infection in young children
in the United States: molecular epidemiological profile and clinical charac-
teristics of a newly emerging respiratory virus. J. Infect. Dis. 194:1276–1282.
20. Kleines, M., S. Scheithauer, A. Rachowitz, K. Ritter, and M. Hausler. 2007.
High prevalence of human bocavirus detected in young children with severe
acute lower respiratory tract disease by use of a standard PCR protocol and
a novel real-time PCR protocol. J. Clin. Microbiol. 45:1032–1034.
21. Kupfer, B., J. Vehreschild, O. Cornely, R. Kaiser, G. Plum, S. Viazov, C.
Franzen, R. L. Tillmann, A. Simon, A. Muller, and O. Schildgen. 2006.
Severe pneumonia and human bocavirus in adult. Emerg. Infect. Dis. 12:
1614–1616.
22. Ma, X., R. Endo, N. Ishiguro, T. Ebihara, H. Ishiko, T. Ariga, and H. Kikuta.
2006. Detection of human bocavirus in Japanese children with lower respi-
ratory tract infections. J. Clin. Microbiol. 44:1132–1134.
23. Maertzdorf, J., C. K. Wang, J. B. Brown, J. D. Quinto, M. Chu, M. de Graaf,
B. G. van den Hoogen, R. Spaete, A. D. Osterhaus, and R. A. Fouchier. 2004.
Real-time reverse transcriptase PCR assay for detection of human meta-
pneumovirus from all known genetic lineages. J. Clin. Microbiol. 42:981–986.
24. Maggi, F., E. Andreoli, M. Pifferi, S. Meschi, J. Rocchi, and M. Bendinelli.
2007. Human bocavirus in Italian patients with respiratory diseases. J. Clin.
Virol. 38:321–325.
25. Manning, A., V. Russell, G. H. Eastick, G. H. Leadbetter, K. Templeton, and











P. Simmonds. 2006. Epidemiological profile and clinical associations of hu-
man bocavirus and other human parvoviruses. J. Infect. Dis. 194:1283–1290.
26. McIntosh, K. 2006. Human bocavirus: developing evidence for pathogenic-
ity. J. Infect. Dis. 194:1197–1199.
27. Monteny, M., H. G. Niesters, H. A. Moll, and M. Y. Berger. 2007. Human
bocavirus in febrile children, The Netherlands. Emerg. Infect. Dis. 13:180–
182.
28. Naghipour, M., L. E. Cuevas, T. Bakhshinejad, W. Dove, and C. A. Hart.
2007. Human bocavirus in Iranian children with acute respiratory infections.
J. Med. Virol. 79:539–543.
29. Neske, F., K. Blessing, F. Tollmann, J. Schubert, A. Rethwilm, H. W. Kreth,
and B. Weissbrich. 2007. Real-time PCR for human bocavirus infections and
phylogenetic analysis. J. Clin. Microbiol. 45:2116–2122.
30. Qu, X. W., Z. J. Duan, Z. Y. Qi, Z. P. Xie, H. C. Gao, W. P. Liu, C. P. Huang,
F. W. Peng, L. S. Zheng, and Y. D. Hou. 2007. Human bocavirus infection,
People’s Republic of China. Emerg. Infect. Dis. 13:165–168.
31. Regamey, N., U. Frey, C. Deffernez, P. Latzin, L. Kaiser, and the Swiss
Paediatric Respiratory Research Group. 2007. Isolation of human bocavirus
from Swiss infants with respiratory infections. Pediatr. Infect. Dis. J. 26:177–
179.
32. Schenk, T., B. Huck, J. Forster, R. Berner, D. Neuman-Haefelin, and V.
Falcone. 2007. Human bocavirus DNA detected by quantitative real-time
PCR in two children hospitalized for lower respiratory tract infection. Eur.
J. Clin. Microbiol. Infect. Dis. 26:147–149.
33. Sloots, T. P., P. McErlean, D. J. Speicher, K. E. Arden, M. D. Nissen, and
I. D. Mckay. 2006. Evidence of human coronavirus HKU1 and human
bocavirus in Australian children. J. Clin. Virol. 35:99–102.
34. Templeton, K. E., C. B. Forde, A. M. Loon, E. C. Claas, H. G. Niesters, P.
Wallace, and W. F. Carman. 2006. A multi-centre pilot proficiency pro-
gramme to assess the quality of molecular detection of respiratory viruses.
J. Clin. Virol. 35:51–58.
35. van den Hoogen, B. G., J. C. de Jong, J. Groen, T. Kuiken, R. de Groot, R. A.
Fouchier, and A. D. Osterhaus. 2001. A newly discovered human pneumo-
virus isolated from young children with respiratory tract disease. Nat. Med.
7:719–724.
36. van den Hoogen, B. G., G. J. J. van Doornum, J. C. Fockens, J. J. Cornel-
issen, W. E. Beyer, R. de Groot, A. D. Osterhaus, and R. A. Fouchier. 2003.
Prevalence and clinical symptoms of human metapneumovirus infection in
hospitalized patients. J. Infect. Dis. 188:1571–1577.
37. Ward, C. L., M. H. Dempsey, C. J. Ring, R. E. Kempson, L. Zhang, D. Gor,
B. W. Snowden, and M. Tisdale. 2004. Design and performance testing of
quantitative real time PCR assays for influenza A and B viral load measure-
ment. J. Clin. Virol. 29:179–188.
38. Watzinger, F., M. Suda, S. Preuner, R. Baumgartinger, K. Ebner, L. Bas-
kova, H. G. Niesters, A. Lawitschka, and T. Lion. 2004. Real-time quanti-
tative PCR assays for detection and monitoring of pathogenic human viruses
in immunosuppressed pediatric patients. J. Clin. Microbiol. 42:5189–5198.
39. Weissbrich, B., F. Neske, J. Schubert, J. Tollmann, K. Blath, K. Blessing,
and H. W. Kreth. 2006. Frequent detection of bocavirus DNA in German
children with respiratory tract infections. BMC Infect. Dis. 6:109–116.
40. Woo, P. C. Y., S. K. P. Lau, C. Chu, H. W. Tsoi, K. H. Chan, and K. Y. Yuen.
2005. Characterization and complete genome sequence of a novel corona-
virus, coronavirus HKU1, from patients with pneumonia. J. Virol. 79:884–
895.
41. Zambon, M. C., J. D. Stockton, J. P. Clewley, and D. M. Fleming. 2001.
Contribution of influenza and respiratory syncytial virus to community cases
of influenza-like illness: an observational study. Lancet 358:1410–1416.




ay 26, 2016 by University of G
roningen
http://jcm.asm.org/
D
ow
nloaded from
 
